Introduction
The pathophysiology of hypertension is not multifactorial in nature, and there is a complex interplay of mechanisms of control and counter-regulatory responses activated by drugs. The problem for clinicians is that it is not really possible to recognise the various clinical phenotypes of hypertension. In other words, the heterogeneity of hypertension remains a clinical problem. 1 Current overwhelming evidence is that the most important treatment concept in the management of hypertension is that treatment should reduce blood pressure to goal levels. 2 The majority of hypertensive patients will need two or more antihypertensive drugs to control their blood pressure at goal. Conceptually, a strong case can be made for the early use of combination therapy in the treatment of hypertension. 3 
Choosing a combination: What is the problem?
The essential problem is that there are very little data from prospective randomised controlled clinical trials that test specific combinations against one another, to guide clinicians in choosing the "superior" combination. Most of the trials that have been carried out tested one drug against another, and then other drugs were added to both treatment arms. Also, in most trials, the second added drug (to both the treatment arms) was the same.
However, there are recommendations in the literature on combinations. 3 These are depicted in the Table I as preferred, acceptable, and unacceptable combinations.
The best evidence from which claims can be made from outcomes in favour of a particular combination regimen, derives from four trials: What evidence is there for angiotensinreceptor blocker combinations?
Currently, dual renin-angiotensin aldosterone system (RAAS) blockade, specifically an ACE inhibitor plus an ARB, should not be used for the treatment of hypertension, as there are no real benefits. Moreover, the risks may outweigh the benefits.S Afr Fam Pract 2012 the majority of patients. 5 The combination of losartan plus HCTZ, as compared to the combination of atenolol plus HCTZ, reduced the composite primary cardiovascular endpoint by 13%. The major benefit of losartan plus HCTZ was in the secondary end-point of stroke (a component of the primary end-point), which was reduced by 25%. This achieved result occurred against the background of an equally reduced level of blood pressure.
In the VALUE trial, 15 245 hypertensives received either an ARB (valsartan) or amlodipine (calcium-channel blocker), and to each arm, HCTZ could be added to control blood pressure over 4.2 years. 6 The primary composite endpoint of cardiac morbidity and mortality was similar in the two arms, comparing valsartan plus HCTZ vs. amlodipine plus HCTZ, but early, better control of blood pressure in the amlodipine arm led to less myocardial infarctions. This trial also linked to the cardiovascular benefit of early blood pressure control in high-risk hypertensives.
The cumulative evidence from these trials supports the view that an ARB plus calcium-channel blocker combination is likely to be associated with better cardiovascular outcomes, than combinations containing beta blockers and thiazide diuretics. 3 Numerous factorial design studies have shown that the combination of a thiazide diuretic plus an ARB (many ARBs) results in fully additive blood pressure reduction. Diuretics activate the RAAS by depleting intravascular volume and addition of ARB, then attenuates this counterregulatory response, and mitigates the hypokalemia induced by the diuretic.
Numerous efficacy and tolerability studies on the combination of an ARB plus a calcium-channel blocker have been carried out, and demonstrated greater blood pressure reductions with the combinations, and significantly more patients achieving goal blood pressure. 7 The combinations tested were amlodipine and valsartan, and amlodipine plus telmisartan, in varying fixed combinations. The combination of amlodipine plus candesartan, as compared to amlodipine alone, also showed increased efficacy for the combination. 8 It is foreseen that all ARBs on the market will be combined with a calcium-channel blocker. In a recent trial, 350 hypertensives were treated with a calcium-channel blocker plus an ARB, or a calcium-channel plus a beta blocker, or a calcium-channel blocker plus a thiazide diuretic, 9 and the clinical effects tested in these three arms. After 3.61 years of treatment, two thirds of the patients achieved target blood pressure, and the three combinations were equally effective in achieving goal blood pressure. Equally, all three combinations had the same reduction of the primary composite outcome of cardiovascular events.
In an efficacy and safety trial, an ARB plus calciumchannel blocker plus HCTZ (triple combination) resulted in significantly more patients reaching goal blood pressure, than the combinations of the ARB plus HCTZ, or ARB plus calcium-channel blocker, or calcium-channel blocker plus HCTZ combinations. 10 This study demonstrates that triple therapy (ARB plus calcium-channel blocker plus HCTZ) can be given safely, can achieve goal blood pressure more often, and can do so promptly.
In summary, there appears to be enough data to support the combination of an ARB plus a diuretic and/or a calciumchannel blocker, either as two separate drugs, or in a fixed combination, with the aim of improving the percentage of hypertensive patients who can reach goal blood pressure.
